Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 402 of 5804
-
New drug targets Hard-to-Treat lung cancer in early trial
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo shows promise in shrinking tough breast cancer before surgery
Disease control Recruiting nowThis phase II trial compares the effect of adding darolutamide to standard therapy versus standard therapy alone before surgery for the treatment of patients with stage II-IIIA androgen receptor positive triple-negative breast carcinoma. Standard therapy before surgery for triple…
Phase: PHASE2 • Sponsor: Vandana Abramson • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Targeted combo aims to shrink breast tumors before surgery
Disease control Recruiting nowThis study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New scan could spot hidden cancers better than current methods
Diagnosis Recruiting nowBackground: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imag…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
Promising drug may halt devastating NMOSD attacks faster
Disease control OngoingNeuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory autoimmune disorder of the central nervous system characterized by the pathogenic anti-aquaporin 4 antibody (AQP4-IgG). The objectives of this study are to assess the efficacy and safety of eculizumab for…
Phase: PHASE2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for lung cancer: combining immunotherapy with targeted local therapy
Disease control Recruiting nowFirst-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 26, 2026 17:24 UTC
-
Can removing the main tumor boost targeted therapy in advanced lung cancer?
Disease control Not yet recruitingThis study is designed to explore whether resecting the primary lung cancer, followed by osimertinib, can improve outcomes for patients with advanced non-small cell lung cancer (NSCLC) harboring sensitizing EGFR mutations (exon 19 deletion or L858R). Patients with stage III-IV NS…
Phase: PHASE2 • Sponsor: Jianxing He • Aim: Disease control
Last updated Jun 26, 2026 18:21 UTC
-
New hope for Tough-to-Treat blood cancers: phase 3 trial launches
Disease control Recruiting nowThis is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy. Primary objective of …
Phase: PHASE3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Could steroids slash death rates from a rare pneumonia?
Disease control Not yet recruitingPneumocystis jirovecii pneumonia (PJP) is one of the common severe complications in immunocompromised patients, with a reported mortality rate of 60-80%. Reducing mortality from PJP is crucial for improving outcomes in critically ill non-HIV immunocompromised patients and allevia…
Phase: PHASE3 • Sponsor: Qingyuan Zhan • Aim: Disease control
Last updated Jun 26, 2026 14:24 UTC
-
Drones vs. ambulances: can flying defibrillators save rural hearts?
Knowledge-focused Recruiting nowThe overall goal of this project is to design, develop, and pilot test an emergency healthcare drone delivery system suitable for rural communities that can deliver AEDs to out-of-hospital cardiac arrest (OHCA) locations more rapidly than can be achieved with current first respon…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New study tests less invasive surgery for severe brain bleeds
Disease control Recruiting nowThis observational cohort study evaluates the safety and effectiveness of minimally invasive surgery (MIS) compared with standard medical management in adults with spontaneous deep intracerebral hemorrhage. Consecutive patients admitted to People's Hospital 115 and Tam Anh Genera…
Sponsor: Huynh Quoc Huy • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New combo aims to wipe out breast cancer before surgery
Disease control Recruiting nowThe goal of this clinical trial is to learn if QL1706 is effective in early HR+/HER2- breast cancer. It will also learn about the safety of QL1706. The main questions it aims to answer are: Does QL1706 combined with neoadjuvant chemotherapy improve the pCR rate of early HR+/HER2…
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for lymphoma patients: drug targets cancer without chemo
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and effectiveness of treating previously untreated Follicular Lymphoma (FL) with odronextamab. The name of the study drug in this research study is: -Odronextamab (a type of monoclonal antibody)
Phase: PHASE2 • Sponsor: Gottfried von Keudell, MD PhD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy aims to slow advanced kidney cancer
Disease control Recruiting nowThe purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on…
Phase: PHASE3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New Same-Day test could transform cervical cancer screening in Low-Resource areas
Diagnosis Recruiting nowThis study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon. Women aged 30-49 years (or 25-49 years if HIV-positive) will undergo…
Phase: NA • Sponsor: University Hospital, Geneva • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
AI app aims to cut heart attack deaths by getting Clot-Busting drugs to patients faster
Disease control Recruiting nowThe aim of the study is to elucidate whether guiding by a novel artificial intelligence assisted mobile application can improve the clinical outcomes of patients in whom "guide wire passing through the lesion" could not be achieved within 120 min after diagnosis of STEMI, compare…
Phase: NA • Sponsor: Shenyang Northern Hospital • Aim: Disease control
Last updated Jun 26, 2026 18:43 UTC
-
Experimental combo therapy targets multiple cancers in new trial
Disease control Recruiting nowPhase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment,…
Phase: PHASE1, PHASE2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Less invasive heart valve fix could rival Open-Heart surgery for tough cases
Disease control ENROLLING_BY_INVITATIONTo evaluate the safety and effectiveness of the Transcatheter aortic valve and retrievable delivery system (VitaFlow Liberty®) for the treatment of severe bicuspid aortic valve (BAV) stenosis.
Phase: NA • Sponsor: Shanghai MicroPort CardioFlow Medtech Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 18:14 UTC
-
Can steroids save lives in severe pneumonia? new trial aims to find out
Disease control Not yet recruitingSevere community-acquired pneumonia (sCAP) has a high mortality rate of 25-50%. Excessive host inflammatory responses contribute to poor outcomes. Corticosteroid therapy may provide benefit; however, the optimal dosage remains unclear, and it is uncertain whether all etiologies (…
Phase: PHASE2, PHASE3 • Sponsor: Qingyuan Zhan • Aim: Disease control
Last updated Jun 26, 2026 13:09 UTC
-
New hope for Hard-to-Treat lymphoma: drug cocktail enters human trials
Disease control Not yet recruitingDiffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in China and worldwide. Although standard immunochemotherapy with Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine (Oncovin), and Prednisone (R-CHOP) achieves durable remis…
Phase: PHASE1, PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 26, 2026 14:55 UTC